methyl (2S,3S,4S,5R,6S)-3,4,5-tris(acetyloxy)-6-(4-{6-[(tert-butyldimethylsilyl)oxy]-3-{4-[2-(piperidin-1-yl)(2H4)ethoxy]benzoyl}-1-benzothiophen-2-yl}phenoxy)oxane-2-carboxylate

• ChemBase编号: 173433
• 分子式: C47H57NO13SSi
• 平均质量: 904.10488
• 单一同位素质量: 903.33198842
• SMILES: c1(ccc2c(c1)sc(c2C(=O)c1ccc(cc1)OCCN1CCCCC1)c1ccc(cc1)O[C@H]1[C@H]([C@H]([C@@H]([C@@H](O1)C(=O)OC)OC(=O)C)OC(=O)C)OC(=O)C)O[Si](C(C)(C)C)(C)C
• Canonical SMILES: COC(=O)[C@@H]1O[C@@H](Oc2ccc(cc2)c2sc3c(c2C(=O)c2ccc(cc2)OCCN2CCCCC2)ccc(c3)O[Si](C(C)(C)C)(C)C)[C@H]([C@H]([C@@H]1OC(=O)C)OC(=O)C)OC(=O)C
• InChI: InChI=1S/C47H57NO13SSi/c1-28(49)56-40-41(57-29(2)50)43(58-30(3)51)46(60-42(40)45(53)54-7)59-34-19-15-32(16-20-34)44-38(36-22-21-35(27-37(36)62-44)61-63(8,9)47(4,5)6)39(52)31-13-17-33(18-14-31)55-26-25-48-23-11-10-12-24-48/h13-22,27,40-43,46H,10-12,23-26H2,1-9H3/t40-,41-,42-,43+,46+/m0/s1
• InChIKey: YPNOPKDREFSCOE-BJWFOKEOSA-N

名称和登记号

名称

• IUPAC标准名: methyl (2S,3S,4S,5R,6S)-3,4,5-tris(acetyloxy)-6-(4-{6-[(tert-butyldimethylsilyl)oxy]-3-{4-[2-(piperidin-1-yl)(^2H₄)ethoxy]benzoyl}-1-benzothiophen-2-yl}phenoxy)oxane-2-carboxylate
• IUPAC传统名: methyl (2S,3S,4S,5R,6S)-3,4,5-tris(acetyloxy)-6-(4-{6-[(tert-butyldimethylsilyl)oxy]-3-{4-[2-(piperidin-1-yl)(^2H₄)ethoxy]benzoyl}-1-benzothiophen-2-yl}phenoxy)oxane-2-carboxylate
• 别名: 4-[6-[[(1,1-Dimethylethyl)dimethylsilyl]oxy]-3-[4-[2-(1-piperidinyl)ethoxy-d4]benzoyl]benzo[b]thien-2-yl]phenyl β-D-Glucopyranosiduronic Acid Methyl Ester 2,3,4-Triacetate; Methyl-1-(6-tert-butyldimethylsylyl-4'-hydroxyraloxifene-d4)-2,3,4-tri-O-acetyl-β-D-glycopyranuronate

登记号

• PubChem SID: 164229343
• PubChem CID: 71750246

理论计算性质

• 质子受体: 10
• 质子供体: 0
• LogD (pH = 5.5): 4.112661
• LogD (pH = 7.4): 5.898736
• Log P: 6.6064
• 摩尔折射率: 229.5635 cm^3
• 极化性: 95.79641 Å^3
• 极化表面积: 162.43 Å^2
• 可自由旋转的化学键: 20
• 里宾斯基五规则: false

分子性质

理化性质

• 溶解度: Chloroform; Methanol
• 外观: Yellow Solid

详细说明

Toronto Research Chemicals - M294419

An intermediate in the synthesis for the metabolite of Raloxifene, a nonsteroidal estrogen receptor mixed agonist/antagonist.